Objectives The goal of this study was to provide with “real world” estimations of the cost-
effectiveness of two direct oral anticoagulants (DOA), dabigatran, and rivaroxaban, versus …

Objectives To assess the cost-effectiveness of dabigatran versus rivaroxaban for the
prevention of stroke and systemic embolism in Chinese patients with non-valvular atrial …

Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …

Objectives Dabigatran has shown to be effective in preventing embolic events in chronic
atrial fibrillation patients, but it's cost-utility has not been assessed in Argentina. Therefore …

Research published in Thrombosis and Haemostasis suggests that dabigatran etexilate is a
highly costeffective treatment for preventing stroke and systemic embolism in patients with …

Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …

Objectives Evidence on cost-effectiveness of direct oral anticoagulants (DOACs) versus
warfarin among atrial fibrillation (AF) patients with varying stroke and bleeding risks is not …

Objectives The aim of this study was to evaluate the effectiveness and safety of Dabigatran
versus Warfarin in “real-word” clinical practice. Methods We conducted a retrospective …

** Background:** Atrial fibrillation (AF) is a chronic sustained heart rhythm disorder
associated with an increased risk of stroke. Apixaban, a new oral anticoagulant, was …

Objectives Dabigatran has a better safety profile and requires less monitoring, but is costlier
than warfarin. This study evaluated the cost-utility of dabigatran relative to warfarin for …